Thyroid and Endocrine Tumors
In thyroid cancer 18F-FDG is well established for detection of noniodine-avid disease in patients with elevated Tg levels. From a prognostic perspective it is known that patients with FDG-avid, high-volume disease (>125 mL) as assessed with CT and PET have markedly reduced survival. Thus FDG PET is a tool for assisting in the clinical decision making for either localized or systemic therapy other than the use of 131I in patients with negative iodine scans and elevated hTg and in patients with suspected local recurrence after thyroidectomy. One important prerequisite of using 18F-PET-CT for this patient is that when using it combined with a 131I-scan or when potentially a radio-iodine-therapy is planned no intravenous contrast should be administered for the diagnostic CT. Here PET-MR can offer the possibility to add a diagnostic morphological dataset to the PET-examination as Gd-based contrast media do not interfere with the use of a 131I-scan or therapy. Additionally PET-MR is expected to be a useful tool in surgical planning and radioactive iodine therapy decisions.
KeywordsThyroid Cancer Attenuation Correction Papillary Thyroid Cancer Medullary Thyroid Cancer 131I Therapy
- 3.Wang W, Macapinlac H, Larson SM, Yeh SDJ, Akhurst T, Finn RD et al (1999) [18F]-2-Fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. JCEM 84(7):2291–2302PubMedGoogle Scholar